C4 therapeutics announces clinical trial collaboration and supply agreement with pfizer for the combination of cemsidomide and elranatamab for the treatment of relapsed/refractory multiple myeloma

Watertown, mass., oct. 01, 2025 (globe newswire) -- c4 therapeutics, inc. (c4t) (nasdaq: cccc), a clinical-stage biopharmaceutical company dedicated to advancing targeted protein degradation science, today announced that it has entered into a clinical trial collaboration and supply agreement with pfizer inc. under the terms of the agreement, pfizer will supply elranatamab (elrexfio®), a b-cell maturation antigen cd3 targeted bispecific antibody (bcmaxcd3 bispecific), to c4t for its upcoming phase 1b trial.
CCCC Ratings Summary
CCCC Quant Ranking